Citius Pharmaceuticals Newsroom

Maxim Group Maintains Citius Pharmaceuticals(CTXR.US) With Buy Rating

Futu NewsNov 28 00:32

Promising Outlook for Citius Pharmaceuticals: Buy Rating Affirmed Amid Product Potential and Strategic Developments

TipRanksNov 28 00:28

D. Boral Capital Downgrades Citius Pharmaceuticals(CTXR.US) to Hold Rating

Futu NewsNov 23 05:32

Citius Pharmaceuticals Cut to Hold From Buy by D. Boral Capital

Dow JonesNov 23 05:28

Citius Pharma Analyst Ratings

BenzingaNov 23 05:18

Maxim Group Maintains Citius Pharmaceuticals(CTXR.US) With Buy Rating, Maintains Target Price $4

Futu NewsNov 12 23:31

Citius Pharmaceuticals' Lymphir and Keytruda Combo Shows Promising Clinical Outcomes, Earning a Buy Rating

TipRanksNov 12 23:27

H.C. Wainwright Maintains Citius Pharmaceuticals(CTXR.US) With Buy Rating, Maintains Target Price $4

Futu NewsNov 12 21:33

Buy Rating for Citius Pharmaceuticals: Promising Clinical Results and Strong Financial Outlook

TipRanksNov 12 20:51

Citius Pharmaceuticals Price Target Maintained With a $4.00/Share by HC Wainwright & Co.

Dow JonesNov 12 20:45

Citius Pharma Analyst Ratings

BenzingaNov 12 06:21

D. Boral Capital Maintains Buy on Citius Pharma, Maintains $6 Price Target

BenzingaNov 12 06:21

Citius Pharma Analyst Ratings

BenzingaAug 19 19:10

EF Hutton Maintains Buy on Citius Pharma, Maintains $6 Price Target

BenzingaAug 19 19:10

Maxim Group Maintains Citius Pharmaceuticals(CTXR.US) With Buy Rating, Maintains Target Price $4

Futu NewsAug 17 01:31

Buy Rating Affirmed for Citius Pharmaceuticals Amid Strategic Oncology Spinout and Promising Lead Product Data

TipRanksAug 17 01:07

Maxim Group Maintains Citius Pharmaceuticals(CTXR.US) With Buy Rating, Maintains Target Price $4

Futu NewsAug 13 19:31

EF Hutton Maintains Buy on Citius Pharma, Maintains $6 Price Target

BenzingaAug 9 01:00

Citius Pharma Analyst Ratings

BenzingaAug 9 00:59

Citius Pharmaceuticals Price Target Maintained With a $6.00/Share by EF Hutton

Dow JonesAug 6 00:28